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Abstract The herbal drug aristolochic acid, a natural
mixture of 8-methoxy-6-nitrophenanthro[3,4-d]-1,3-diox-
ole-5-carboxylic acid (AAI) and 6-nitrophenanthro[3,4-d]-
1,3-dioxole-5-carboxylic acid (AAII), is derived from
Aristolochia species and is the cause of two nephropathies.
Ingestion of aristolochic acid is associated with the
development of urothelial tumors linked with aristolochic
acid nephropathy and is implicated in the development of
Balkan endemic nephropathy-associated urothelial tumors.
The O-demethylated metabolite of AAI, 8-hydroxyaris-
tolochic acid (AAIa), is the detoxification product of AAI
generated by its oxidative metabolism. Whereas the for-
mation of AAIa from AAI by cytochrome P450 (CYP)
enzymes has been found in vitro and in vivo, this
metabolite has not been found from AAII as yet. Therefore,
the present study has been designed to compare the
amenability of AAI and AAII to oxidation; experimental
and theoretical approaches were used for such a study. In
the case of experimental approaches, the enzyme (CYP)-
mediated formation of AAIa from both carcinogens was
investigated using CYP enzymes present in subcellular
microsomal fractions and recombinant CYP enzymes. We
found that in contrast to AAI, AAII is oxidized only by
several CYP enzymatic systems and their efficiency is
much lower for oxidation of AAII than AAI. Using the
theoretical approaches, such as flexible in silico docking
methods and ab initio calculations, contribution to expla-
nation of these differences was established. Indeed, the
results found by both used approaches determined the
reasons why AAI is better oxidized than AAII; the key
factor causing the differences in AAI and AAII oxidation is
their different amenability to chemical oxidation.
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Introduction
Aristolochic acid (AA), the natural extract of plants of the
Aristolochiaceae family, is a mixture of structurally related
nitrophenanthrene carboxylic acids, with two major compo-
nents aristolochic acid I (8-methoxy-6-nitrophenanthro[3,4-d]-
1,3-dioxole-5-carboxylic acid, AAI; Fig. 1) and aristolochic
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acid II (6-nitrophenanthro[3,4-d]-1,3-dioxole-5-carboxylic
acid, AAII). AA is found exclusively in plants of both the
Aristolochia and Asarum genera of the family Aris-
tolochiaceae in all parts. Aristolochia herbs have been used
for remedies throughout the world since antiquity and they
remain in use today, particularly in Chinese herbal medi-
cine [1–9]. Both AAI and AAII are mutagenic and
genotoxic [1, 10–13] forming covalent adducts with DNA,
the genotoxic end points generated by their reductive
activation in vitro and in vivo (Fig. 1) (reviewed in [1–9]).
In 2012 AA was classified as carcinogenic to humans
(group 1) acting by a genotoxic mechanism by the Inter-
national Agency for Research on Cancer (IARC) [14].
Today, there is compelling evidence that human exposure
to AA leads to chronic renal disease and upper urinary tract
cancer known as aristolochic acid nephropathy (AAN)
[14, 15], which is now recognized as a global disease [9].
AA is also considered as the major cause of another chronic
renal disease associated with urothelial malignancy known
as Balkan endemic nephropathy (BEN) [2, 3, 6–9, 15].
The metabolism of AA has been studied in several
species demonstrating that the major metabolites found in
urine and feces are the aristolactams I and II [16–18]
produced by six electron reductions of the nitro group.
Other minor metabolites formed through O-demethylation
and denitration have also been reported. The only
metabolites identified in humans so far are the aristolac-
tams I and II found in urine [16].
On comparing the AAI with AAII, significantly higher
levels of AAI-derived DNA adducts than adducts derived
from AAII were found in several organs of rats and mice
exposed to these compounds in vivo [19–23] and in various
enzymatic systems in vitro [24–30]. However, in C3H/He
mice exposed to equivalent doses of AAI and AAII, lower
levels of AAII-derived DNA adducts were found only in
non-target organs such as liver, stomach, intestine and
lung, in contrast to the primary target tissues, renal cortex,
medulla and bladder (urothelial cells) [22], where the same
extent of formation of DNA adducts was found. The
apparent discrepancies among the studies [19–23] might be
Fig. 1 Activation and detoxication pathways of AAI. dA-AAI
7-(deoxyadenosin-N6-yl)aristolactam I, dG-AAI 7-(deoxyguanosin-
N2-yl)aristolactam I, CYP1A1/2 cytochrome P450 1A1 and 1A2,
CYP2C cytochrome P450 2C, NQO1 NAD(P)H:quinone oxidoreduc-
tase, UGT UDP glucuronosyltransferase, SULT sulfotransferase
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attributed to several reasons such as the use of various
animal models, utilization of a variety of treatment proto-
cols and/or employing the different AA–DNA adduct
detection methods.
Differences in levels of AAI- and AAII-derived DNA
adducts found in most studies performed in vivo and
in vitro might be also caused by a different enzymatic
conversion of these carcinogens, leading both to their
activation to DNA adducts and their detoxification. Indeed,
finding that AAII is a poorer substrate of the reduction-
catalyzing enzymes located in microsomal and cytosolic
subcellular fractions than AAI has been already demon-
strated in several studies [25, 28, 29]. However, even
though the efficiency of biotransformation enzymes to
oxidize AAI was determined, such information is missing
for AAII.
It has been shown that the genotoxic and carcinogenic
properties caused by AAI- and AAII–DNA adduct forma-
tion is mediated by their partial reduction to the reactive
acylnitrenium ion, which is a prerequisite for their gener-
ation in vivo and in vitro [7, 8]. Several human enzymes
capable of activating AA by nitroreduction have been
identified and include cytosolic NAD(P)H:quinone oxi-
doreductase (NQO1) [28–31] and microsomal enzymes,
mainly cytochrome P450 (CYP) 1A1 and CYP1A2, while
NADPH:CYP oxidoreductase (POR) is less efficient
[25, 26, 32–35]. In addition to the abilities of CYP1A1 and
1A2 to reduce AAI and AAII, these enzymes are also
efficient in AAI oxidative detoxification to form the O-
demethylated metabolite, 8-hydroxyaristolochic acid
(AAIa) [33, 34, 36–40] (Fig. 1). This dual role of CYP1A1
and 1A2 is an important feature, because a balance
between reductive activation and oxidative detoxification
reactions of AAI is considered to be a critical determinant
in the development of AAN and BEN. However, until the
present time the knowledge of the participation of AAII in
these processes is scarce, because the oxidative metabolism
of AAII is essentially not known; no metabolites formed by
direct oxidation of AAII have been identified in human and
animal models in vivo [16–18], and no data on metabolism
of AAII to its oxidative metabolites in vitro have been
reported.
Therefore, the present study is primarily focused on the
investigation of the CYP-mediated oxidation of AAII
in vitro and secondly on a comparison of AAII-reaction
product(s) with those of AAI. To this end, rat and human
hepatic microsomal subcellular fractions containing CYPs
and recombinant CYP enzymes were used to analyze their
potency to catalyze the oxidation of AAI and AAII.
Moreover, in silico docking, employing soft–soft (flexible)
docking procedure, was used to study the interactions of
AAI and AAII with the CYP-compounds I, the highly
reactive CYP intermediates that are responsible for the
CYP-mediated oxidations of their substrates [41, 42], of the
most efficient CYP enzymes oxidizing AAI [39]. Furher,
ab initio calculations were employed to investigate the
amenability of AAI and AAII to oxidation. We believe that
such a study might shed more light on mechanisms of the
CYP-mediated metabolism to AAI and AAII and their
contribution to AAN and BEN development.
Results and discussion
Oxidation of AAI and AAII to AAIa by CYP
enzymatic systems
To identify the efficiencies of individual CYPs to oxidize
AAII, three approaches were employed: (1) the use of rat
and human hepatic microsomes, (2) the use of specific
inducers of CYP enzymes to modulate the levels of indi-
vidual CYPs in rat microsomes and (3) the use of rat and
human recombinant CYPs.
Oxidation of the AA natural mixture, consisting of AAI
and AAII as the major components, and that of pure AAI or
AAII by rat hepatic microsomes was analyzed by HPLC
(Fig. 2). Incubation of AA, where AAI and AAII are pre-
sent, or AAI alone, with rat microsomes and NADPH (a
coenzyme of the CYP-monooxygenase system) leads to the
formation of AAIa (Fig. 2a, b).
In contrast, no AAII metabolites were detectable when
AAII was incubated with these microsomes under the same
conditions; no AAIa or other peak products of AAII were
detectable by HPLC under the used conditions (Fig. 2c).
Likewise, no AAIa or other peak products of AAII were
found when human hepatic microsomes were used (results
not shown).
To investigate whether AAII might be oxidized to AAIa
by rat hepatic microsomes enriched with individual CYP
enzymes, we used selective CYP inducers (Fig. 3). Using
this approach, we evaluated which of the CYPs can par-
ticipate in the formation of AAIa from AAI and AAII in
these rat hepatic microsomes (Fig. 3). In the case of AAI,
as described in our former studies [36, 38], hepatic
microsomes isolated from rats treated with Sudan I (as an
inducer of CYP1A), phenobarbital (PB) (as an inducer of
CYP2B and 2C), ethanol (EtOH) (which induces
CYP2E1), and pregnenolone carbonitrile (PCN) (as an
inducer of CYP3A) O-demethylated AAI to AAIa. The
highest level of AAIa was formed by microsomes of rats
treated with Sudan I (rich in CYP1A), followed by
microsomes of rats treated with PB (rich in CYP2B and
2C) and microsomes of rats untreated—control (Fig. 3a).
In contrast to these results, the AAIa formation from AAII
was detectable only using microsomes of rats pre-treated
with PCN (as an inducer of CYP3A), followed by those
Comparison of the oxidation of carcinogenic aristolochic acid I and II by microsomal…
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with PB (rich in CYP2B and 2C) and those with ethanol
(rich in CYP2E1) (Fig. 3b). These microsomes were,
however, much less effective to form AAIa from AAII than
from AAI.
In our former studies, we examined the activity of indi-
vidual human and rat CYPs to oxidize AAI to AAIa using
recombinant enzymes heterologously expressed in micro-
somes of baculovirus-infected insect cells (SupersomesTM)
in combination with their reductase, NADPH:CYP reductase
(POR) [33, 38, 39]. In these studies, it was demonstrated that
human CYPs were more effective in AAI oxidation than
their rat orthologs. Human and rat CYPs of the 1A sub-
family are the major enzymes oxidizing AAI. Other CYPs
such as human and rat CYPs of the 2C subfamily and human
CYP3A (CYP3A4/5), 2D6, 2E1 and 1B1, also form AAIa,
but with much lower efficiency than CYP1A (see Fig. 2a in
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Fig. 2 HPLC chromatogram of AA oxidation metabolites formed by
hepatic microsomes of control rats incubated with AA and NADPH
(a), that of AAI oxidation metabolites by the same microsomal
fraction incubated with AAI and NADPH (b), and AAII metabolites
formed by the same microsomal fraction incubated with AAII and
NADPH (c). HPLC was carried out with a Nucleosil 100-5 C18,
25 9 4.0 mm, 5 mm (Macherey-Nagel) column, using a linear
gradient of acetonitrile (20–60% acetonitrile in 55 min) in
100 mmol dm-3 triethylamonium acetate with a flow rate of
0.6 cm-3 min-1. A Dionex HPLC pump P580 with UV/VIS UVD
170S/340S spectrophotometer detector set at 254 nm was used. Peaks
were integrated with CHROMELEONTM 6.01 integrator. A peak
eluting at retention time (r.t.) 22.1 (22.7) min was identified as AAIa
using mass spectroscopy analysis [38]
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our previous study [39]). Only rat CYP enzymes of the 1A
and 2C subfamilies oxidize AAI of which CYP1A enzymes
are more active than CYP2C enzymes (see Fig. 2b in the
former study [39]).
Of human and rat CYP enzymes expressed in the same
CYP systems (SupersomesTM), only rat CYP of the 3A
subfamily, CYP3A1, but not CYP3A2, was capable of
oxidizing AAII to AAIa (Fig. 4). Other tested CYPs such
as those of CYPs of the 1A, 2B, 2C and 2E subfamilies
were inefficient in this reaction (results not shown).
Origin of differences in CYPs-mediated oxidation
between AAI and AAII
Experimentally observed differences in CYPs-mediated
oxidation between AAI and AAII were further investigated
using a combination of theoretical methods. The efficiency
of CYP enzymes, which were able to oxidize AAI to form
AAIa in vitro, was much higher than their ability to oxidize
AAII (Fig. 3). Several properties of the molecules might be
responsible for this variation in their metabolism: (1) dif-
ferent nature of their interaction with the CYP enzymes or
(2) different susceptibility of AAI and AAII toward oxi-
dation reaction leading to AAIa metabolite.
Binding of AAI and AAII to the active sites
of CYP1A1, 1A2 and 3A4
O-Demethylation of AAI and C8-ring hydroxylation of
AAII proceed (Fig. 5) via the CYP-mediated attack of
activated oxygen atom of compound I on the target
carbons.
The high affinity binding of a substrate (AAI or AAII) is
necessary for efficient enzymatic activity; therefore, we
used soft–soft, flexible molecular docking to generate and
rank possible binding poses of AAI and AAII in active sites
of selected CYP enzymes. The substrate orientation in the
narrow active site of mentioned enzymes is also important,
as only suitable substrate position, allowing sterical contact
between reacting groups, facilitate the catalysis. Thus,
differences among the abilities of the CYP enzymes to O-
demethylate AAI or to directly mono-oxygenate carbon 8
of AAII might be caused by the affinities of AAI and AAII
to these enzymes and their binding orientations in their
active sites.
Previously, we investigated binding of AAI to the active
site of the compounds I of human CYP1A1, 1A2 and 3A4.
These CYPs O-demethylate AAI, but with different
effectiveness and contribute efficiently to this reaction (see
Fig. 5 in our former study [39]). The estimated free ener-
gies of AAI binding together with the reaction group
distances are shown in Table 1. The results indicate that
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Fig. 3 AAIa formation by rat hepatic microsomes from AAI (a) [38]
and AAII (b). Values represent mean ± standard deviations from
three independent experiments. ***P\ 0.001, **P\ 0.01,
*P\ 0.05 (Student’s t test), significantly different from incubations
of AAI with control microsomes. ND not detectable
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Fig. 4 AAIa formation by rat CYP3A1 in SupersomesTM. Values
represent mean ± standard deviations from three independent
experiments
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CYP1A subfamily enzymes, which are more efficient in
AAI oxidation, show higher binding affinity toward the
AAI then CYP3A4.
Now, we evaluated binding of AAII to the same set of
enzymes (CYP1A1, 1A2 and 3A4). The estimated free
energies of AAII binding together with the reaction group
distances are shown in Table 2. The results found in this
docking procedure indicate that AAII is best bound to
human CYP1A1; however unlike AAI, AAII seems to be a
better substrate of CYP3A4 than CYP1A2. It is predicted
that CYP3A4 binds AAII more tightly and also in a more
suitable position (Table 2; Fig. 6).
Small differences in binding free energies between AAI
and AAII are insufficient to fully explain the experimental
observation that overall oxidation is much lower for AAII
than AAI. Nevertheless, the fact that tested CYP enzymes
bind the AAI and AAII molecules with similar affinities
and that AAII is not metabolized imply that AAII might
competitively inhibit AAI oxidation catalyzed by CYPs.
AAII inhibits the formation of AAIa generated
from AAI
To confirm the predicted results on binding of AAII in the
active site of tested CYPs, we investigated the effect of
AAII on AAIa formation from AAI catalyzed by the
microsomal CYP enzyme system. Rat hepatic microsomes
were incubated with 0.01 mmol dm-3 AAI, both alone and
O
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α- -hydroxylated Aristolochic acid I
O
O
COO
NO2
Aristolochic acid II (AAII)
+ O
Step Ia
+ O
Step Ib
-HCHO
Step 
II 
C
Fig. 5 Scheme of AAI and AAII oxidation to AAIa
Table 1 The predicted binding free energies and distances facilitat-
ing O-demethylation of AAI bound in selected CYP complexes
Simulated
system
The most stable productive orientations of AAI in the
complex with CYP
Estimated free energy
of binding/kJ mol-1
O(comp I)-OCH3
Distance/A˚a
CYP1A1 -29.3 4.44
CYP1A2 -32.0 4.90
CYP3A4 -25.0 3.67
a Distance between the carbon in the methoxy group of AAI and
oxygen atom on heme iron in the complex of an activated CYP
enzyme (compound I) with AAI; see Fig. 5
Table 2 The predicted binding free energies and distances facilitat-
ing C8-hydroxylation of AAII bound in selected CYP complexes
Simulated
system
The most stable productive orientations of AAII in the
complex with CYP
Estimated free energy
of binding/kJ mol-1
O(comp I)-C8
Distance/A˚a
CYP1A1 -30.9 3.50
CYP1A2 -25.5 4.13
CYP3A4 -27.0 3.70
a Distance between the C8 carbon in AAII and oxygen atom on heme
iron in the complex of an activated CYP enzyme (compound I) with
AAII; see Fig. 5
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in the presence of AAII (0.001, 0.01 or 0.1 mmol dm-3).
AAII in this experiment competitively inhibited the for-
mation of AAIa from AAI, with an inhibition constant
value (Ki) of 11.3 lM. This finding supports results that
were found by flexible in silico docking.
Thermodynamics of AAI and AAII conversion
to AAIa
Because the interaction with CYP enzymes was not able to
explain a significant difference in AAI and AAII
metabolism, we further seek the interpretation in their
diverse general amenability to oxidation. The AAIa for-
mation from AAI and AAII proceeds through different
reaction mechanisms. O-Demethylation of AAI to AAIa
proceeds in two steps: first is a-C-hydroxylation initiated
by the attack of the carbon atom of the AAI methoxy group
by oxygen originally bound to compound I, which leads to
the formation of the a-C-hydroxylated intermediate (step Ia
in Fig. 5). This unstable intermediate spontaneously
decomposes into AAIa forming formaldehyde as a by-
product (step Ib in Fig. 5), while oxidation of AAII pro-
ceeded by one-step mono-oxygenation of aromatic carbon
8 (step II in Fig. 5). To test the hypothesis that the observed
metabolic difference may originate from the different
reaction energetics, we performed ab initio calculations
[29] of the reaction steps mentioned above.
The predicted values of reaction free energies (DG in
Table 3) representing individual reaction oxidation steps
were predicted using the gas phase ab initio simulation and
also using three solvation models: the polarizable con-
ductor calculation model (CPCM), integral equation
formalism model (IEFPCM) and the Langevin dipoles
model (LD). All reaction steps predicted by these models
show negative values of reaction free energies (DG0
0
rea);
therefore, they are thermodynamically feasible. Interest-
ingly, the predicted relative difference between initial steps
(Ia and II) of AAIa formation ðDDGrea ðAAIAAIIÞÞ always
favor AAI over AAII by 9.2–22.6 kJ mol-1 (Table 3). In
addition, the decomposition of a-C-hydroxylated AAI is
also energetically favored; therefore, it further supports
AAI metabolism resulting in the overall preference of AAI
oxidation by 41–82.8 kJ mol-1 over AAII (Table 3). Such
significant differences in the reaction free energy DG of
AAIa formation could contribute to the large disparity in
hydroxylation potential of AAI and AAII. We propose that
this effect can be one of the major reasons why AAI is
better oxidized than AAII.
Conclusions
The data presented in this study advance our knowledge on
the oxidative metabolism of the major components of the
natural plant alkaloid and the human carcinogen AA
(containing mainly AAI and AAII) by human and rat CYPs
and contribute to explain the reasons causing the differ-
ences in efficiency in oxidation of these substances to an
oxidation metabolite AAIa. Employing rat and human
hepatic microsomes containing CYPs and recombinant
CYP enzymes, we demonstrated that AAII is oxidized by
these enzymes to a much lower extent (if any) than AAI.
This phenomenon, found in the present study in in vitro
experiments, suggests that AAII is also hardly oxidized in
Fig. 6 The binding orientations found in molecular docking calcu-
lations facilitating C8-hydroxylation of AAII bound in human
CYP1A1 (a); CYP1A2 (b); and CYP3A4 (c). AAII, heme and amino
acid residues interacting ligand are shown as bold sticks and sticks,
respectively. Red ribbon represents a part of the I helix (color
figure online)
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organisms in vivo, being metabolized only by the reductive
activation forming AAII–DNA adducts [3, 5, 6]. Indeed, no
direct evidence for the formation of AAIa from AAII was
found in vivo [17, 18].
The flexible in silico docking modeling studies
demonstrated almost no differences in binding of AAI and
AAII to three of the CYP enzymes that are most effective
in AAI oxidation. This finding indicates that both AAs are
bound to the active site of CYP-compounds I with similar
affinities, which is the first and necessary step for their
oxidation. This suggestion was also confirmed by finding
that AAII competitively inhibits O-demethylation of AAI
to AAIa catalyzed by these enzymes. However, the only
AAI is oxidized, whereas essentially no C8-ring hydroxy-
lation of AAII is catalyzed by the CYP systems. These
results strongly suggest that binding of AAI and AAII to
CYP enzymes is not responsible for differences in AAI and
AAII oxidation.
Ab initio calculations employed in this study indicated
that the possibility of AAI and AAII being subjected to
chemical oxidation differs significantly; the carbon of the
methoxy group of AAI is attacked by oxygen (from com-
pound I) forming the unstable a-C-hydroxylated metabolite
that is easily decomposed to formaldehyde and AAIa. This
decomposition is capable of facilitating the overall pro-
duction of AAIa from AAI, because it is finally
energetically more feasible than the C8-ring hydroxylation
of AAII. Thus, these results demonstrate that the key factor
causing the differences in AAI and AAII oxidation is their
different amenability to oxidation.
Experimental
Aristolochic acid mixture (AA, 38% AAI, 58% AAII) and
NADPH (as tetrasodium salt; *98% purity) were pur-
chased from Sigma Chemical Co. (St Louis, MO, USA).
AAI (CAS Number 313-67-7) and AAII (CAS Number
475-80-9) were purified from the commercially available
AA mixture by reverse-phase chromatography as described
previously [23].
Animal experiments and isolation of hepatic
microsomes
All animal experiments were conducted in accordance with
the Regulations for the Care and Use of Laboratory Ani-
mals (311/1997, Ministry of Agriculture, Czech Republic),
which is in compliance with the Declaration of Helsinki.
Male Wistar rats (*125–150 g, AnLab, Czech Republic)
placed in cages in temperature- and humidity-controlled
rooms were acclimatized for 5 days and maintained at
22 C with a 12 h light/dark period. Standardized diet (ST-
1 diet from Velaz, Czech Republic) and water were pro-
vided ad libitum. Rats were treated with inducers of
CYP1A (Sudan I), CYP2B (PB), ethanol (CYP2E1) and
CYP3A (PCN) as follows: (1) Ten 5-week-old male Wistar
rats (*125–150 g) were injected i.p. with 20 mg kg-1
b.w. Sudan I in maize oil once a day for three consecutive
days as reported previously [38]. Animals in the control
group received the same volume of maize oil on the 3 days.
Rats were killed 24 h after the last treatment by cervical
dislocation. (2) Ten 5-week-old male Wistar rats
(*125–150 g) were pretreated with PB (0.1% in drinking
water for 6 days) as described previously [38]. Animals in
the control group received drinking water. Rats were killed
after treatment by cervical dislocation. (3) Ten 5-week-old
male Wistar rats (*125–150 g) were pretreated with
ethanol (10% in drinking water for 7 days) as described
previously [43]. Animals in the control group received
drinking water. Rats were killed after treatment by cervical
dislocation. (4) Ten 5-week-old male Wistar rats
(*125–150 g) were injected i.p. with 50 mg kg-1 b.w.
PCN dissolved in maize oil for four consecutive days as
reported previously [44]. Animals in the control group
received the same volume of maize oil. Rats were killed
24 h after the last treatment by cervical dislocation. For all
treatment groups, livers of the animals were removed
Table 3 Standard reaction free energies corresponding to individual reaction steps of AAI and AAII oxidation predicted by quantum chemical
approach considering gas phase state and three solvation models CPCM, IEFPCM and LD (for methods, see [29])
Reaction steps (Fig. 5) DG0
0
rea/kJ mol
-1
AAI ? AAIa
DDGrea ðAAIAAIIÞ/kJ mol
-1
AAII ? AAIa
Solvation model Ia.a Ib. Ia. ? Ib. II.a Ia. - II. Ia. ? Ib. - II.
Gas phase -488 -20 -508 -467 -20.5 -41.0
Water (CPCM) -487 -41 -528 -477 -9.21 -50.6
Water (IEFPCM) -491 -36 -527 -476 -15.5 -51.9
Water (LD) -522 -60 -582 -500 -22.6 -82.8
a In these steps, free oxygen atom was consider as an oxidant
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immediately after killing, frozen in liquid nitrogen and
stored at -80 C until isolation of microsomal fractions.
Pooled microsomes were prepared from ten rat livers/group
as reported [25] and used for experiments of our present
study. As the control microsomes, those from rats treated
with 1 cm3 of sunflower oil (by gavage, see above) were
utilized. The activities of the CYP marker substrates in
these control microsomes did not differ significantly from
those in other control microsomes. Microsomal fractions
were stored at -80 C until analysis. Protein concentra-
tions in the microsomal fractions were assessed using the
bicinchoninic acid protein assay with bovine serum albu-
min as a standard [45].
AAIa formation by rat and human hepatic
microsomes and SupersomesTM
The incubation mixtures, in a final volume of 0.250 cm3,
consisted of 100 mmol dm-3 potassium phosphate buffer
(pH 7.4), 1 mmol dm-3 NADPH, 1 mg human or rat
hepatic microsomal protein and 0.01 mmol dm-3 AAI or
AAII or 0.02 mmol dm-3 AA. Incubations with micro-
somes were carried out at 37C for 20 min (AAI oxidation
to AAIa was linear up to 25 min [33, 38]. Control incu-
bations were carried out (1) without microsomes, (2)
without NADPH or (3) without AAI, AAII or AA. Human
hepatic microsomes (male and female) and SupersomesTM,
microsomes isolated from insect cells transfected with
baculovirus constructs containing cDNA of single rat CYPs
(CYP1A1, CYP1A2, CYP2A1, CYP2A2, CYP2B1,
CYP2C6, CYP2C11, CYP2C12, CYP2C13, CYP2D1,
CYP2D2, CYP2E1, CYP3A1 and CYP3A2) or of single
human CYPs (CYP1A1, CYP1A2, CYP2A6, CYP2B6,
CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4) and
expressing POR and/or cytochrome b5, were obtained from
Gentest Corp and tested for their efficiencies to oxidize
AA. Incubation mixtures in a final volume of 0.250 cm3
consisted of 100 mmol dm-3 potassium phosphate buffer
(pH 7.4), 1 mmol dm-3 NADPH, 50 nmol dm-3 CYPs in
SupersomesTM and 0.01 mmol dm-3 AAI or AAII. AA
metabolites including AAIa were analyzed by high-per-
formance liquid chromatography (HPLC) as described
below and in the previous studies [33, 36, 38].
Inhibition studies
Incubation mixtures, in a final volume of 0.250 cm3, con-
sisted of 100 mmol dm-3 potassium phosphate buffer (pH
7.4), 1 mmol dm-3 NADPH, 1 mg rat hepatic microsomal
protein and 0.01 mmol dm-3 AAI without or with 0.001,
0.01 or 0.1 mmol dm-3 AAII. Mixtures were incubated at
37 C for 25 min. Formation of AAIa was analyzed by
HPLC [33, 36, 38]. The value of the inhibition constant Ki
for AAII was determined by the Dixon plot [46].
HPLC analysis of AAIa formation
AA, AAI or AAII and their metabolites (including AAIa)
were extracted from incubations with ethyl acetate
(2 9 1 cm3), the extracts were evaporated to dryness and
the residues redissolved in 0.03 cm3 of methanol and
subjected to reverse-phase HPLC. HPLC was performed
with a reversed-phase column (Nucleosil 100-5 C18,
25 9 4.0 mm, 5 mm; Macherey-Nagel) preceded by a
C-18 guard column, using a linear gradient of acetonitrile
(20–60% acetonitrile in 55 min) in 100 mmol dm-3 tri-
ethylammonium acetate with a flow rate of
0.5 mmol dm-3 min-1. A Dionex HPLC pump P580 with
UV/VIS UVD 170S/340S spectrophotometer detector was
set at 250 nm and a CHROMELEONTM 6.01 integrator
was used for the integration of peaks. A peak eluting at
retention time (r.t.) 22.1 (22.7) min was identified as AAIa
using mass spectroscopy analysis [38].
Molecular docking of AAI and AAII into compounds
I of human CYP1A1, 1A2 and 3A4
The X-ray based coordinates of human CYP1A1 (2.6 A˚
resolution, PDB ID 4I8V) [47], human CYP1A2 (1.95 A˚
resolution, PDB ID 2HI4) [48] and CYP3A4 (2.74 A˚ res-
olution, PDB ID 1W0G) were used as starting structures
for modeling of AAI or AAII interactions with the ground
state of CYP enzymes. During structure preparation,
hydrogen atoms were added and crystallographic water and
ligand molecules were removed, and the usual protonation
states and Gasteiger partial charges were assigned to all
residues, except for the atomic charge of the ferric ion of
the heme cofactor, for which a value more consistent with a
metal in octahedral coordination was used [49]. The
geometries and charges of a ligands (AAI and AAII) were
predicted using ab initio calculations on the Hartree–Fock
level of theory in conjunction with the 6-31 ? G(d) basis
set. These ab initio calculations were performed with
program Gaussian 03 [50].
We employed a hybrid global–local Lamarckian genetic
algorithm implemented in Autodock v4.2.6 program [51]
suite to evaluate binding free energies and preferred
binding modes for studied compounds. All rotatable bonds
of the ligands and 10–11 selected amino acid side chains,
CYP1A1 (S122, F123, N221, F224, F258, D313, D320,
T321, V382, L496, T497), CYP1A2 (T124, F125, T223,
F226, F260, D313, D320, T321, L382, L497, T498) and
CYP3A4 (F108, S119, F213, F215, F241, F304), were
allowed to rotate freely. We performed an extensive search
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(5000 docking runs per system) of the most preferred
binding modes of an AAI molecule within a 57 9 47 9 47
grid box centered on the substrate binding cavity. Similar
resulting structures (RMSD lower than 2.0 A˚) were
grouped and finally sorted by binding free energy of the
best binding structure within each cluster. As a result, a set
of binding modes with similar binding energies was
obtained for every system. We assume that only the ori-
entations with a sufficiently short distance between carbon
of the methoxy group of AAI or the C8 carbon atom of
AAII and the activated oxygen atom in the CYP compound
I would facilitate the AAI or AAII oxidation.
Quantum chemical calculation
The geometry optimizations of all reactants and products
were done using ab initio approach implemented in
Gaussian09 program suite [52]. All calculations were per-
formed on the Hartree–Fock (HF) level of theory in
conjunction with 6-31?G(d) basis set. The thermal cor-
rected Gibbs free energies were in all models obtained
from electronic calculations and harmonic vibration fre-
quencies of these optimized structures. The reaction Gibbs
free energies of individual reaction steps evaluated here
were calculated as the total free energies of products minus
the total free energies of reactants. Initially, the geometry
optimization was performed without considering the sol-
vent (in gas phase), and then solvent effect was estimated
by performing energy optimizations using the polarizable
conductor calculation model (CPCM) [53], integral equa-
tion formalism model (IEFPCM) [52] with default atomic
radii. The solvation free energy of the considered com-
pounds was also predicted using Langevin dipole model
(LD) with the ChemSol program v2.1 [53]. Merz–Kollman
partial atomic charges obtained from ab initio calculations
served as an input for these LD calculations.
Statistical analyses
For statistical data analysis, we used Student’s t test. All
P values are two-tailed and considered significant at the
0.05 level.
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